{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:41:44Z","timestamp":1791492104328,"version":"4.3.4"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018818","name":"National Research, Development and Innovation Office","doi-asserted-by":"publisher","award":["K125377"],"award-info":[{"award-number":["K125377"]}],"id":[{"id":"10.13039\/501100018818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018818","name":"National Research, Development and Innovation Office","doi-asserted-by":"publisher","award":["FK134863"],"award-info":[{"award-number":["FK134863"]}],"id":[{"id":"10.13039\/501100018818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018818","name":"National Research, Development and Innovation Office","doi-asserted-by":"publisher","award":["K143549"],"award-info":[{"award-number":["K143549"]}],"id":[{"id":"10.13039\/501100018818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018818","name":"National Research, Development and Innovation Office","doi-asserted-by":"publisher","award":["FK139269"],"award-info":[{"award-number":["FK139269"]}],"id":[{"id":"10.13039\/501100018818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003825","name":"Hungarian Academy of Sciences","doi-asserted-by":"publisher","award":["LP2017\u201318\/2017"],"award-info":[{"award-number":["LP2017\u201318\/2017"]}],"id":[{"id":"10.13039\/501100003825","id-type":"DOI","asserted-by":"publisher"}]},{"name":"New National Excellence Program of the Ministry of Human Capacities","award":["UNKP- 20-5-SZTE-161"],"award-info":[{"award-number":["UNKP- 20-5-SZTE-161"]}]},{"name":"New National Excellence Program of the Ministry of Human Capacities","award":["UNKP-21-3-SZTE-94"],"award-info":[{"award-number":["UNKP-21-3-SZTE-94"]}]},{"name":"Janos Bolyai Research","award":["BO\/00598\/19\/5"],"award-info":[{"award-number":["BO\/00598\/19\/5"]}]},{"DOI":"10.13039\/501100015269","name":"Hungarian Government","doi-asserted-by":"publisher","award":["NTP-NFT\u00d6-22-B-0130"],"award-info":[{"award-number":["NTP-NFT\u00d6-22-B-0130"]}],"id":[{"id":"10.13039\/501100015269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015269","name":"Hungarian Government","doi-asserted-by":"publisher","award":["NTP-NFT\u00d6-22-B-0131"],"award-info":[{"award-number":["NTP-NFT\u00d6-22-B-0131"]}],"id":[{"id":"10.13039\/501100015269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>Crohn\u2019s disease [CD] and ulcerative colitis [UC] require lifelong treatment and patient monitoring. Current biomarkers have several limitations; therefore, there is an unmet need to identify novel biomarkers in inflammatory bowel disease [IBD]. Previously, the role of plasminogen activator inhibitor 1 [PAI-1] was established in the pathogenesis of IBD and suggested as a potential biomarker. Therefore, we aimed to comprehensively analyse the selectivity of PAI-1 in IBD, its correlation with disease activity, and its potential to predict therapeutic response.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Blood, colon biopsy, organoid cultures [OC], and faecal samples were used from active and inactive IBD patients and control subjects. Serpin E1 gene expressions and PAI-1 protein levels and localisation in serum, biopsy, and faecal samples were evaluated by qRT-PCR, ELISA, and immunostaining, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The study population comprised 132 IBD patients [56 CD and 76 UC] and 40 non-IBD patients. We demonstrated that the serum, mucosal, and faecal PAI-1 concentrations are elevated in IBD patients, showing clinical and endoscopic activity. In responders [decrease of eMayo\u2005\u22653 in UC; or SES-CD\u2005\u200550% in CD], the initial PAI-1 level decreased significantly upon successful therapy. OCs derived from active IBD patients produced higher concentrations of PAI-1 than the controls, suggesting that epithelial cells could be a source of PAI-1. Moreover, faecal PAI-1 selectively increases in active IBD but not in other organic gastrointestinal diseases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The serum, mucosal, and faecal PAI-1 concentration correlates with disease activity and therapeutic response in IBD, suggesting that PAI-1 could be used as a novel, non-invasive, disease-specific, faecal biomarker in patient follow-up.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjad160","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T16:08:12Z","timestamp":1695744492000},"page":"392-405","source":"Crossref","is-referenced-by-count":10,"title":["Plasminogen Activator Inhibitor 1 Is a Novel Faecal Biomarker for Monitoring Disease Activity and Therapeutic Response in Inflammatory Bowel Diseases"],"prefix":"10.1093","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2764-3925","authenticated-orcid":false,"given":"Boldizs\u00e1r","family":"J\u00f3j\u00e1rt","sequence":"first","affiliation":[{"name":"Ladon Therapeutics Ltd , Szeged , Hungary"},{"name":"Department of Medicine, University of Szeged , Szeged , Hungary"},{"name":"ELKH-USZ Momentum Epithelial Cell Signaling and Secretion Research Group, University of Szeged , Szeged , Hungary"},{"name":"HCEMM-USZ Molecular Gastroenterology Research Group, University of Szeged , Szeged , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3842-9094","authenticated-orcid":false,"given":"Tam\u00e1s","family":"Res\u00e1l","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Szeged , Szeged , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4432-9380","authenticated-orcid":false,"given":"Di\u00e1na","family":"Kata","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Institute of Laboratory Medicine, University of Szeged , Szeged , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6842-6521","authenticated-orcid":false,"given":"T\u00fcnde","family":"Moln\u00e1r","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Szeged , Szeged , Hungary"},{"name":"ELKH-USZ Momentum Epithelial Cell Signaling and Secretion Research Group, University of Szeged , Szeged , Hungary"},{"name":"HCEMM-USZ Molecular Gastroenterology Research Group, University of Szeged , Szeged , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8534-0068","authenticated-orcid":false,"given":"P\u00e9ter","family":"Bacsur","sequence":"additional","affiliation":[{"name":"Ladon Therapeutics Ltd , Szeged , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6547-9102","authenticated-orcid":false,"given":"Vikt\u00f3ria","family":"Szab\u00f3","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Szeged , Szeged , Hungary"},{"name":"ELKH-USZ Momentum Epithelial Cell Signaling and Secretion Research Group, University of Szeged , Szeged , Hungary"},{"name":"HCEMM-USZ Molecular Gastroenterology Research Group, University of Szeged , Szeged , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2379-139X","authenticated-orcid":false,"given":"\u00c1rp\u00e1d","family":"Varga","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Szeged , Szeged , Hungary"},{"name":"ELKH-USZ Momentum Epithelial Cell Signaling and Secretion Research Group, University of Szeged , Szeged , Hungary"},{"name":"HCEMM-USZ Molecular Gastroenterology Research Group, University of Szeged , Szeged , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0749-5061","authenticated-orcid":false,"given":"Kata Judit","family":"Sz\u00e1nt\u00f3","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Szeged , Szeged , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8906-0840","authenticated-orcid":false,"given":"Petra","family":"Pallagi","sequence":"additional","affiliation":[{"name":"Ladon Therapeutics Ltd , Szeged , Hungary"},{"name":"Department of Medicine, University of Szeged , Szeged , Hungary"},{"name":"ELKH-USZ Momentum Epithelial Cell Signaling and Secretion Research Group, University of Szeged , Szeged , Hungary"},{"name":"HCEMM-USZ Molecular Gastroenterology Research Group, University of Szeged , Szeged , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3329-8136","authenticated-orcid":false,"given":"Imre","family":"F\u00f6ldesi","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Institute of Laboratory Medicine, University of Szeged , Szeged , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4913-7599","authenticated-orcid":false,"given":"Tam\u00e1s","family":"Moln\u00e1r","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Szeged , Szeged , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5768-3090","authenticated-orcid":false,"given":"J\u00f3zsef","family":"Mal\u00e9th","sequence":"additional","affiliation":[{"name":"Ladon Therapeutics Ltd , Szeged , Hungary"},{"name":"Department of Medicine, University of Szeged , Szeged , Hungary"},{"name":"ELKH-USZ Momentum Epithelial Cell Signaling and Secretion Research Group, University of Szeged , Szeged , Hungary"},{"name":"HCEMM-USZ Molecular Gastroenterology Research Group, University of Szeged , Szeged , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0599-182X","authenticated-orcid":false,"given":"Klaudia","family":"Farkas","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Szeged , Szeged , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,26]]},"reference":[{"key":"2024030118335716800_CIT0001","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","article-title":"The global burden of IBD: from 2015 to 2025","volume":"12","author":"Kaplan","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2024030118335716800_CIT0002","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/apt.14373","article-title":"Systematic review and meta-analysis: assessment of factors affecting disability in inflammatory bowel disease and the reliability of the inflammatory bowel disease disability index","volume":"47","author":"Lo","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2024030118335716800_CIT0003","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/ajg.2009.579","article-title":"The natural history of adult Crohn\u2019s disease in population-based cohorts","volume":"105","author":"Peyrin-Biroulet","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"2024030118335716800_CIT0004","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of tight control management on Crohn\u2019s disease [CALM]: a multicentre, randomised, controlled phase 3 trial","volume":"390","author":"Colombel","year":"2017","journal-title":"Lancet"},{"key":"2024030118335716800_CIT0005","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1136\/gutjnl-2019-318256","article-title":"Tight control for Crohn\u2019s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial","volume":"69","author":"Panaccione","year":"2020","journal-title":"Gut"},{"key":"2024030118335716800_CIT0006","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1002\/ibd.22861","article-title":"Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies","volume":"18","author":"Mao","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"2024030118335716800_CIT0007","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1177\/1756283X16638833","article-title":"Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease","volume":"9","author":"Kopylov","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"key":"2024030118335716800_CIT0008","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/00325481.2018.1503919","article-title":"Fecal markers in the management of inflammatory bowel disease","volume":"130","author":"Dai","year":"2018","journal-title":"Postgrad Med"},{"key":"2024030118335716800_CIT0009","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1136\/gutjnl-2021-324855","article-title":"Calprotectin: from biomarker to biological function","volume":"70","author":"Jukic","year":"2021","journal-title":"Gut"},{"key":"2024030118335716800_CIT0010","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/1756283X14553384","article-title":"The role and utility of faecal markers in inflammatory bowel disease","volume":"8","author":"Lehmann","year":"2015","journal-title":"Therap Adv Gastroenterol"},{"key":"2024030118335716800_CIT0011","doi-asserted-by":"crossref","first-page":"eaat0852","DOI":"10.1126\/scitranslmed.aat0852","article-title":"PAI-1 augments mucosal damage in colitis","volume":"11","author":"Kaiko","year":"2019","journal-title":"Sci Transl Med"},{"key":"2024030118335716800_CIT0012","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.7150\/ijbs.75890","article-title":"Plasminogen activator inhibitor-1 potentiates neutrophil infiltration and tissue injury in colitis","volume":"19","author":"Wang","year":"2023","journal-title":"Int J Biol Sci"},{"key":"2024030118335716800_CIT0013","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","article-title":"Development of a Crohn\u2019s disease activity index. National Cooperative Crohn\u2019s Disease Study","volume":"70","author":"Best","year":"1976","journal-title":"Gastroenterology"},{"key":"2024030118335716800_CIT0014","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study","volume":"317","author":"Schroeder","year":"1987","journal-title":"N Engl J Med"},{"key":"2024030118335716800_CIT0015","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1002\/ibd.21300","article-title":"Endoscopic evaluation of Crohn\u2019s disease activity: comparison of the CDEIS and the SES-CD","volume":"16","author":"Sipponen","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"2024030118335716800_CIT0016","doi-asserted-by":"crossref","first-page":"480","DOI":"10.5946\/ce.2022.108","article-title":"Endoscopic activity in inflammatory bowel disease: clinical significance and application in practice","volume":"55","author":"Kim","year":"2022","journal-title":"Clin Endosc"},{"key":"2024030118335716800_CIT0017","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41374-019-0300-3","article-title":"Mouse pancreatic ductal organoid culture as a relevant model to study exocrine pancreatic ion secretion","volume":"100","author":"Moln\u00e1r","year":"2020","journal-title":"Lab Invest"},{"key":"2024030118335716800_CIT0018","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/ibd.21432","article-title":"New therapeutic targets in ulcerative colitis: the importance of ion transporters in the human colon","volume":"17","author":"Farkas","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"2024030118335716800_CIT0019","doi-asserted-by":"crossref","first-page":"e167645","DOI":"10.1172\/jci.insight.167645","article-title":"Ora1 calcium channel inhibition prevents progression of chronic pancreatitis","volume":"8","author":"Szab\u00f3","year":"2023","journal-title":"JCI Insight"},{"key":"2024030118335716800_CIT0020","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1053\/j.gastro.2011.07.050","article-title":"Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett\u2019s epithelium","volume":"141","author":"Sato","year":"2011","journal-title":"Gastroenterology"},{"key":"2024030118335716800_CIT0021","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-230X-12-5","article-title":"Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study","volume":"12","author":"Manz","year":"2012","journal-title":"BMC Gastroenterol"},{"key":"2024030118335716800_CIT0022","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/BF00403280","article-title":"Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis","volume":"34","author":"Juhan-Vague","year":"1991","journal-title":"Diabetologia"},{"key":"2024030118335716800_CIT0023","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/jcb.26146","article-title":"Plasminogen Activator Inhibitor Type-1 as a Regulator of Fibrosis","volume":"119","author":"Rabieian","year":"2018","journal-title":"J Cell Biochem"},{"key":"2024030118335716800_CIT0024","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0162-3109(86)90033-0","article-title":"Secretion of interleukin 1\/leucocytic pyrogen from endotoxin-stimulated human alveolar macrophages is unaffected by indomethacin","volume":"12","author":"Eden","year":"1986","journal-title":"Immunopharmacology"},{"key":"2024030118335716800_CIT0025","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.4049\/jimmunol.135.6.3978","article-title":"Lipopolysaccharide [LPS] stimulates fresh human monocytes to lyse actinomycin D-treated WEHI-164 target cells via increased secretion of a monokine similar to tumor necrosis factor","volume":"135","author":"Chen","year":"1985","journal-title":"J Immunol"},{"key":"2024030118335716800_CIT0026","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000163737","article-title":"Interleukin-6 expression in immunologically elicited murine macrophages","volume":"60","author":"Scales","year":"1992","journal-title":"Pathobiology"},{"key":"2024030118335716800_CIT0027","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S1053-2498(02)00403-5","article-title":"Upregulation of PAI-1 is mediated through TGF-beta\/Smad pathway in transplant arteriopathy","volume":"21","author":"Dong","year":"2002","journal-title":"J Heart Lung Transplant"},{"key":"2024030118335716800_CIT0028","doi-asserted-by":"crossref","first-page":"14914","DOI":"10.1016\/S0021-9258(17)42691-3","article-title":"Purification of an inhibitor of plasminogen activator [antiactivator] synthesized by endothelial cells","volume":"259","author":"van Mourik","year":"1984","journal-title":"J Biol Chem"},{"key":"2024030118335716800_CIT0029","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/00365521.2013.870597","article-title":"Prevalence of hypercoagulable disorders in inflammatory bowel disease","volume":"49","author":"Kohoutova","year":"2014","journal-title":"Scand J Gastroenterol"},{"key":"2024030118335716800_CIT0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ibd\/izz104","article-title":"The cost of inflammatory bowel disease: an initiative from the Crohn\u2019s & Colitis Foundation","volume":"26","author":"Kt","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"2024030118335716800_CIT0031","first-page":"s51","article-title":"Economic implications of inflammatory bowel disease and its management","volume":"22","author":"Mehta","year":"2016","journal-title":"Am J Manag Care"},{"key":"2024030118335716800_CIT0032","doi-asserted-by":"crossref","first-page":"101602","DOI":"10.1016\/j.bpg.2019.02.004","article-title":"What is the role of C-reactive protein and fecal calprotectin in evaluating Crohn\u2019s disease activity","volume":"38","author":"Ma","year":"2019","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"2024030118335716800_CIT0033","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1097\/MEG.0000000000001284","article-title":"Fecal calprotectin is not superior to serum C-reactive protein or the Harvey-Bradshaw index in predicting postoperative endoscopic recurrence in Crohn\u2019s disease","volume":"30","author":"Verdejo","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2024030118335716800_CIT0034","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/MCG.0000000000001244","article-title":"Noninvasive methods for assessing inflammatory bowel disease activity in pregnancy: a systematic review","volume":"53","author":"Tandon","year":"2019","journal-title":"J Clin Gastroenterol"},{"key":"2024030118335716800_CIT0035","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s10620-014-3362-5","article-title":"Hematologic indices as surrogate markers for monitoring thiopurine therapy in IBD","volume":"60","author":"Kopylov","year":"2015","journal-title":"Dig Dis Sci"},{"key":"2024030118335716800_CIT0036","first-page":"304","article-title":"Therapeutic drug monitoring in inflammatory bowel disease","volume":"27","author":"Kopylov","year":"2014","journal-title":"Ann Gastroenterol"},{"key":"2024030118335716800_CIT0037","first-page":"2708909","article-title":"Upper gastrointestinal Crohn\u2019s Disease: literature review and case presentation","volume":"2019","author":"Aggarwal","year":"2019","journal-title":"Case Rep Gastrointest Med"},{"key":"2024030118335716800_CIT0038","doi-asserted-by":"crossref","first-page":"e0255974","DOI":"10.1371\/journal.pone.0255974","article-title":"A comparison of diagnostic performance between two quantitative rapid fecal calprotectin assays in detecting active inflammatory bowel disease","volume":"16","author":"Lee","year":"2021","journal-title":"PLoS One"},{"key":"2024030118335716800_CIT0039","doi-asserted-by":"crossref","first-page":"679264","DOI":"10.3389\/fmed.2021.679264","article-title":"Clinical value of fecal calprotectin in predicting mucosal healing in patients with ulcerative colitis","volume":"8","author":"Chen","year":"2021","journal-title":"Front Med [Lausanne]"},{"key":"2024030118335716800_CIT0040","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.2147\/JIR.S342846","article-title":"Combined use of fecal biomarkers in inflammatory bowel diseases: Oncostatin M and calprotectin","volume":"14","author":"Cao","year":"2021","journal-title":"J Inflamm Res"},{"key":"2024030118335716800_CIT0041","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/apt.12221","article-title":"A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn\u2019s disease","volume":"37","author":"Naismith","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"2024030118335716800_CIT0042","doi-asserted-by":"crossref","DOI":"10.1111\/jgh.14950","article-title":"Is fecal calprotectin an accurate marker in the management of Crohn\u2019s disease","volume":"35","author":"Vernia","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"2024030118335716800_CIT0043","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1515\/cclm-2018-1063","article-title":"Faecal calprotectin in inflammatory bowel diseases: a review focused on meta-analyses and routine usage limitations","volume":"57","author":"Laserna-Mendieta","year":"2019","journal-title":"Clin Chem Lab Med"},{"key":"2024030118335716800_CIT0044","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1136\/archdischild-2018-316584","article-title":"Calprotectin instability may lead to undertreatment in children with IBD","volume":"105","author":"Haisma","year":"2020","journal-title":"Arch Dis Child"},{"key":"2024030118335716800_CIT0045","doi-asserted-by":"crossref","first-page":"6690","DOI":"10.1038\/s41598-021-86251-w","article-title":"Serum biomarkers confirming stable remission in inflammatory bowel disease","volume":"11","author":"Kessel","year":"2021","journal-title":"Sci Rep"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjad160\/52029708\/jjad160.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/18\/3\/392\/56814095\/jjad160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/18\/3\/392\/56814095\/jjad160.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T18:35:07Z","timestamp":1709318107000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/18\/3\/392\/7282409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,26]]},"references-count":45,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,9,26]]},"published-print":{"date-parts":[[2024,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad160","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3,1]]},"published":{"date-parts":[[2023,9,26]]}}}